Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Sold by Verition Fund Management LLC

Verition Fund Management LLC lessened its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 84.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 33,530 shares of the biotechnology company's stock after selling 186,297 shares during the period. Verition Fund Management LLC owned about 0.06% of Aldeyra Therapeutics worth $181,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. US Bancorp DE acquired a new stake in Aldeyra Therapeutics in the 3rd quarter valued at $30,000. SG Americas Securities LLC purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter valued at about $38,000. Laidlaw Wealth Management LLC lifted its position in Aldeyra Therapeutics by 32.6% during the 2nd quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 4,150 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Aldeyra Therapeutics by 14.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company's stock worth $72,000 after acquiring an additional 2,729 shares in the last quarter. Finally, King Wealth Management Group grew its position in Aldeyra Therapeutics by 24.5% in the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 2,700 shares in the last quarter. Hedge funds and other institutional investors own 59.71% of the company's stock.

Aldeyra Therapeutics Stock Performance

Shares of ALDX traded up $0.27 during mid-day trading on Tuesday, reaching $5.33. 557,806 shares of the stock traded hands, compared to its average volume of 493,761. The stock has a fifty day simple moving average of $5.15 and a 200 day simple moving average of $4.75. Aldeyra Therapeutics, Inc has a 12-month low of $2.71 and a 12-month high of $6.55. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.25). On average, equities research analysts predict that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.